SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: October 2023 (Report No. 4)
Commission file number: 001-37600
NANO DIMENSION LTD.
(Translation of registrant’s name into English)
2 Ilan Ramon
Ness Ziona 7403635 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
This Report of Foreign Private
Issuer on Form 6-K consists of: (i) Nano Dimension Ltd. (the “Registrant”) press release issued on October 18, 2023, titled
“Nano Dimension Announces Additional Governance Enhancements and Convening of an Extraordinary General Meeting of Shareholders”
which is attached hereto as Exhibit 99.1; and (ii) the Registrant’s Notice of Meeting, Proxy Statement and Proxy Card for the Extraordinary
General Meeting of Shareholders to be held on Wednesday, December 13, 2023, which are attached hereto as Exhibits 99.2, 99.3 and 99.4,
respectively
Only shareholders of record
who hold Ordinary Shares, nominal value NIS 5.00 each, or American Depositary Shares representing Ordinary Shares, of the Registrant at
the close of business on November 8, 2023, will be entitled to notice of and to vote at the Meeting and any postponements or adjournments
thereof.
The first three paragraphs
and the section titled “Forward Looking Statements” in the press release attached hereto as Exhibit 99.1 and Exhibits 99.2,
99.3 and 99.4 are incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-255960, 333-233905, 333-251155, 333-252848, 333-251004 and 333-249184)
and Form S-8 (File No. 333-214520, 333-248419 and 333-269436), filed with the Securities and Exchange Commission,
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
Exhibit No. |
|
|
99.1 |
|
Press release issued by Nano Dimension Ltd. on October 18, 2023, titled “Nano Dimension Announces Additional Governance Enhancements and Convening of an Extraordinary General Meeting of Shareholders”. |
99.2 |
|
Notice of an Extraordinary General Meeting of Shareholders to be held on December 13, 2023, at 4:00 p.m., Israel time. |
99.3 |
|
Proxy Statement for the Extraordinary General Meeting of Shareholders to be held on December 13, 2023, at 4:00 p.m., Israel time. |
99.4 |
|
Proxy Card for the Extraordinary General Meeting of Shareholders to be held on December 13, 2023, at 4:00 p.m., Israel time. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Nano Dimension Ltd. |
|
(Registrant) |
|
|
|
Date: October 18, 2023 |
By: |
/s/ Tomer Pinchas |
|
Name: |
Tomer Pinchas |
|
Title: |
Chief Operating Officer |
2
Exhibit 99.1
Nano Dimension Announces Additional Governance
Enhancements
and
Convening of an Extraordinary General Meeting
of Shareholders
Following Shareholder Feedback and Input from
Governance Experts in Reference to the 9/2023 Shareholders’ Meeting:
| ● | Two
Directors to Step Down - Making 6 Independent Directors Out of a Total
7 (CEO Being the Sole Non-Independent) |
| ● | Chairman
of the Board and CEO Roles Were Separated: Dr. Yoav Nissan-Cohen Was Recently Appointed as Non-Executive Chairman |
| ● | U.S.
Army 4-Star General (Ret.) Michael X. Garrett, Former Commanding General of U.S. Army
Forces Command, a Director of Textron, Appointed to Nano Dimension’s Board |
Changes are Part of an Ongoing Planned Process
Aimed at Strengthening Corporate Governance Practices
Waltham, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE)
-- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leading supplier of Additively
Manufactured Electronics and multi-dimensional polymer, metal & ceramic Additive Manufacturing 3D printers, today announced that it
will hold an Extraordinary General Meeting of Shareholders (the “EGM”) on December 13th, 2023, at which shareholders
will be asked to approve compensation for the Company’s Directors, including the Chairman of the Board and Nano Dimension’s
Chief Executive Officer. In addition, Nano Dimension today announced the continuation of its corporate governance enhancements to further
align the Company’s profile with gold standards and best practices based on shareholder feedback and input from governance experts,
Institutional Shareholder Services and Glass Lewis, prior to the previous Annual General Meeting on September 7th, 2023.
As part of setting the board to be efficient and
effective, Nano Dimension has followed ISS recommendations from March and September 2023: Igal Rotem and Amit Dror are stepping down from
the Board effective immediately as part of a planned transition. Amit Dror will also resign from his position as Customer Success Officer.
With these changes, Nano Dimension’s Board
has been reduced, since September 2023, from nine to seven directors, with all six non-executive directors being independent.
These changes follow the previously announced
separation of the Company’s Chairman and CEO roles, under which independent director Dr. Yoav Nissan-Cohen was appointed Chairman
of the Board, as announced on September 15th, 2023.
Yoav Stern, CEO of Nano Dimension, commented,
“We intend to continue corporate governance enhancements with refreshed Board composition and Board rightsizing, as well as recruiting
unique and highly qualified additions to our present leadership. Our new Chairman, Dr. Yoav Nissan-Cohen, is already highly effective
in helping us prepare the Company’s board leadership for the years to come. And we have more improvements planned, most of them
aimed to fulfill our main goal: Supporting long term shareholders’ interests.”
Dr. Nissan-Cohen added, “Over the past few
months, we have made important changes to our Board to promote independent oversight. Today’s announcement is a continuation of
these efforts, as we have considered feedback from our shareholders and independent governance experts. Separately, as part of our effort,
Mr. Rotem has left the Board, and I would like to thank him for his contribution over the last 18 months.”
Mr. Stern concluded, “This is an opportunity
for all of Nano Dimension’s teams since it is inception in 2014, and me personally, to thank a very special individual, Mr. Amit
Dror. He is the co-founder of the Company and its previous CEO. Amit is a visionary and a relentless leader and entrepreneur. His strength
and commitment over so many years is part and parcel of what Nano Dimension’s spirit is today. Thank you, Amit. You will always
be a part of Nano Dimension, and vice versa.”
Additional Information Regarding the EGM
The
EGM will be held December 13th, 2023 at 16:00 p.m., Israel time at the Company’s headquarters in Israel and the following
items will be put to a vote:
| 1. | Approval of cash annual fee for all non-executive directors as of October 1st, 2023. |
| 2. | Approval of a compensation package for the Company’s Chairman of the Board, Dr. Yoav Nissan-Cohen,
as of September 13th, 2023. |
| 3. | Approval of a compensation package for the Company’s
Chief Executive Officer, Mr. Yoav Stern, as of January 1st, 2024. |
The Company’s proxy statement will be mailed
to all ADS holders in due course following the November 8th, 2023, record date and will contain any properly presented agenda
items from shareholders.
About Nano Dimension
Nano Dimension’s (Nasdaq: NNDM) vision
is to transform existing electronics and mechanical manufacturing into Industry 4.0 environmentally friendly & economically efficient
precision additive electronics and manufacturing – by delivering solutions that convert digital designs to electronic or mechanical
devices – on demand, anytime, anywhere.
Nano Dimension’s strategy is driven by
the application of deep learning based AI to drive improvements in manufacturing capabilities by using self-learning & self-improving
systems, along with the management of a distributed manufacturing network via the cloud.
Nano Dimension serves over 2,000 customers
across vertical target markets such as aerospace & defense, advanced automotive, high-tech industrial, specialty medical technology,
R&D and academia. The company designs and makes Additive Electronics and Additive Manufacturing 3D printing machines and
consumable materials. Additive Electronics are manufacturing machines that enable the design and development of High-Performance-Electronic-Devices
(Hi-PED®s). Additive Manufacturing includes manufacturing solutions for production of metal, ceramic, and specialty polymers based
applications – from millimeters to several centimeters in size with micron precision.
Through the integration of its portfolio of
products, Nano Dimension is offering the advantages of rapid prototyping, high-mix-low-volume production, IP security, minimal environmental
footprint, and design-for-manufacturing capabilities, which is all unleashed with the limitless possibilities of additive manufacturing.
For more information, please visit www.nano-di.com.
Forward Looking Statements
This press release contains forward-looking statements
within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking
statements. For example, Nano Dimension is using forward-looking statements in this press release when it discusses potential additional
governance enhancements. Because such statements deal with future events and are based on Nano Dimension’s current expectations,
they are subject to various risks and uncertainties. Actual results, performance, or achievements of Nano Dimension could differ materially
from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this
press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in
Nano Dimension’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023,
and in any subsequent filings with the SEC. Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release
any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites
is not incorporated by reference into this press release. Nano Dimension is not responsible for the contents of third-party websites.
NANO DIMENSION INVESTOR RELATIONS CONTACT
Investor Relations | ir@nano-di.com
NANO DIMENSION MEDIA CONTACT
Kal Goldberg / Bryan Locke / Kelsey Markovich
| NanoDimension@fgsglobal.com
3
Exhibit 99.2
NANO DIMENSION LTD.
NOTICE OF AN EXTRAORDINARY
GENERAL MEETING OF SHAREHOLDERS
Notice is hereby given that an Extraordinary General
Meeting of Shareholders (the “Meeting”) of Nano Dimension Ltd. (the “Company”) will be held at the
offices of the Company at 2 Ilan Ramon, Ness Ziona 7403635, Israel (the “Company’s Registered Address”), on December
13, 2023, at 16:00 p.m., Israel time.
The Meeting is being called for the following
purposes:
| 1. | To approve a cash annual fee for all non-executive directors
as of October 1, 2023. |
| 2. | To approve a compensation package for the Company’s
Non-Executive Chairman of the board of directors, Dr. Yoav Nissan-Cohen, as of September 13, 2023. |
| 3. | To approve a compensation package for the Company’s
Chief Executive Officer, Mr. Yoav Stern, as of January 1, 2024. |
Board Recommendation
The Company’s
board of directors (the “Board of Directors”) unanimously recommends that you vote FOR of all proposals, which are
described in the attached proxy statement (the “Proxy Statement”).
Record Date
Shareholders of record
at the close of business on November 8th, 2023 (the “Record Date”) are entitled to notice of and to vote
at the Meeting, either in person or by appointing a proxy to vote in their stead at the Meeting (as detailed below).
Required Vote and
Voting Procedures
Each of Proposals No.
1, 2 and 3 to be presented at the Meeting requires a Special Majority, as defined in the Proxy Statement herein, of votes in person or
represented by proxy at the Meeting.
How You Can Vote
A form of proxy for use
at the Meeting is attached to the Proxy Statement, and a voting instruction form, together with a return envelope, will be sent to holders
of American Depositary Shares (“ADS”) representing the Company’s Ordinary Shares of a nominal value of NIS 5.00
each (“Ordinary Shares”). By appointing “proxies,” shareholders and ADS holders may vote at the Meeting
whether or not they attend. If a properly executed proxy in the attached form is received by the Company at least four (4) hours prior
to the Meeting, all of the Ordinary Shares represented by the proxy shall be voted as indicated on the form. ADS holders should return
their voting instruction form by the date set forth therein. Subject to applicable law and the rules of the Nasdaq Stock Market, in the
absence of instructions, the Ordinary Shares represented by properly executed and received proxies will be voted “FOR” each
proposed resolution to be presented at the Meeting for which the Board of Directors recommends a “FOR.”
Shareholders may revoke their proxies or voting
instruction form (as applicable) in accordance with Section 9 of the Israeli Companies Law, 5759-1999 regulations (proxy and positions
statements), by filing with the Company (in the case of holders of Ordinary Shares) or with the Bank of New York Mellon (in the case of
holders of ADSs) a written notice of revocation or duly executed proxy or voting instruction form (as applicable) bearing a later date.
Shareholders holding
Ordinary Shares may also (i) vote their shares in person at the Meeting by presenting a certificate of ownership that complies with the
Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting), 5760 – 2000, as amended, as proof of
ownership of the shares on the Record Date, or (ii) send such certificate along with a duly executed proxy and including a copy of their
identity card, passport or certification of incorporation, as the case may be, to the Company’s Registered Address, Attention: Mr.
Tomer Pinchas, not less than 48 hours prior to the Meeting. In addition, shareholders of record (other than the Bank of New York Mellon)
can surrender their shares with the Bank of New York Mellon in order to convert such shares to ADSs and vote as a holder of ADSs with
the Bank of New York Mellon, provided such shareholders of record complete such conversion and registration of said shares to ADSs with
the Bank of New York Mellon prior to the Record Date. ADS holders should return their proxies by the date set forth on their voting instruction
card.
ADS holders should return
their proxies by the date set forth on their voting instruction card.
Sincerely,
Dr. Yoav Nissan-Cohen, Chairman of the
Board of Directors
October 18, 2023
Exhibit 99.3
NANO DIMENSION LTD.
2 ILAN RAMON, NESS ZIONA,
7403635 ISRAEL
PROXY STATEMENT
EXTRAORDINARY GENERAL
MEETING OF SHAREHOLDERS
TO BE HELD ON DECEMBER
13, 2023
The enclosed proxy is
being solicited by the board of directors (the “Board of Directors”) of Nano Dimension Ltd. (the “Company”)
for use at the Company’s Extraordinary General Meeting of Shareholders (the “Meeting”) to be held on December
13, 2023, at 16:00 p.m., Israel time, or at any adjournment or postponement thereof.
Upon the receipt of a
properly executed proxy in the form enclosed, the persons named as proxies therein will vote the ordinary shares, par value New Israeli
Shekels 5.00 each, of the Company (the “Ordinary Shares”) covered thereby in accordance with the directions of the
shareholders executing the proxy. In the absence of such directions, and except as otherwise mentioned in this Proxy Statement, the Ordinary
Shares represented thereby will be voted in favor of the proposals described in this Proxy Statement.
Two or more shareholders
present, personally or by proxy, holding not less than twenty-five percent (25%) of the Company’s outstanding Ordinary Shares, shall
constitute a quorum for the Meeting. If within half an hour from the time the Meeting is convened a quorum is not present, the adjourned
meeting shall be held on the same day, December 13, 2023, at 18:00 p.m. Israel time. If a quorum is not present at the adjourned meeting
within half an hour from the time appointed for such meeting, any number of shareholders present personally or by proxy shall be deemed
a quorum and shall be entitled to deliberate and to resolve in respect of the matter for which the Meeting was convened. Abstentions and
broker non-votes are counted as Ordinary Shares present for the purpose of determining a quorum.
Pursuant to the Israeli
Companies Law, 5759-1999 (the “Companies Law”), each of Proposals No. 1, 2 and 3 described hereinafter requires the
affirmative vote of at least a majority of the votes of shareholders present and voting, provided that either (i) such a majority includes
at least the majority of the votes of shareholders who (a) are not controlling shareholders of the Company and (b) do not have personal
interest in the approval of the proposal (abstentions will not be taken into account); or (ii) the total number of votes against such
proposal among the shareholders mentioned in clause (i) above does not exceed 2% of the total voting rights in the Company (a “Special
Majority”).
For this purpose, “personal interest”
is defined under the Companies Law as: (1) a shareholder’s personal interest in the approval of an act or a transaction of the Company,
including (i) the personal interest of any of his or her relatives (which includes for these purposes foregoing shareholder’s spouse,
siblings, parents, grandparents, descendants, and spouse’s descendants, siblings, and parents, and the spouse of any of the foregoing);
(ii) a personal interest of a corporation in which a shareholder or any of his/her aforementioned relatives serve as a director or the
chief executive officer, owns at least 5% of its issued share capital or its voting rights or has the right to appoint a director or chief
executive officer; and (iii) a personal interest of an individual voting via a power of attorney given by a third party (even if the empowering
shareholder has no personal interest), and the vote of an attorney-in-fact shall be considered a personal interest vote if the empowering
shareholder has a personal interest, and all with no regard as to whether the attorney-in-fact has voting discretion or not, but (2) excludes
a personal interest arising solely from the fact of holding shares in the Company.
For this purpose, a “controlling shareholder”
is any shareholder that can direct the Company’s activities (other than by means of being a director or office holder of the Company).
A person is presumed to be a controlling shareholder if he or she holds or controls, by himself or together with others, one half or more
of any one of the “means of control” of a company; in the context of a transaction with an interested party, a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company,
is also presumed to be a controlling shareholder. “Means of control” is defined as any one of the following: (i) the right
to vote at a general meeting of a company, or (ii) the right to appoint directors of a company or its chief executive officer.
In accordance with the
Companies Law, and regulations promulgated thereunder, any shareholder of the Company holding at least 1% of the outstanding voting rights
of the Company for the Meeting may submit to the Company a proposed additional agenda item for the meeting, to
Mr. Itay Mandel, the Company’s Global Head of Legal, or Mr. Tomer Pinchas, the Company’s Chief Operating Officer, e-mail address:
itay.mandel@nano-di.com or tomer.p@nano-di.com, respectively, no later than October 25, 2023.
Shareholders or holders
of the Company’s American Depositary Shares (“ADS”) wishing to express their position on an agenda item for this
Meeting may do so by submitting a written statement (a “Position Statement”) to the Company’s offices, c/o Mr.
Tomer Pinchas, at 2 Ilan Ramon, Ness Ziona, Israel. Any Position Statement received will be furnished to the U.S. Securities and Exchange
Commission (“SEC”) on a Report on Form 6-K and will be made available to the public on the SEC’s website at www.sec.gov.
Position Statements should be submitted to the Company no later than December 4th, 2023. A shareholder is entitled to contact
the Company directly and receive the text of the proxy card and any Position Statement. The Board of Directors’ response to the
Position Statement will be submitted no later than December 8th, 2023.
One shareholder or more
holding Ordinary Shares which reflect 5% or more of the Company’s share capital and voting rights (11,755,349 Ordinary Shares) and
whoever holds 5% of the Company’s share capital and voting rights is entitled to examine the Proxy Statement and voting material,
during the Company’s business days and working hours, according to applicable law.
It is noted that there
may be changes on the agenda after publishing this Proxy Statement, and there may be Position Statements which can be published. Therefore,
the most updated agenda will be furnished to the SEC on a Report on Form 6-K and will be made available to the public on the SEC’s
website at www.sec.gov.
PROPOSAL 1
TO APPROVE A CASH ANNUAL FEE TO ALL NON-EXECUTIVE
DIRECTORS OF THE COMPANY
In accordance with feedback from the Company’s
shareholders, and a deliberative process by the Board of Directors as well as after consultation with US corporate governance advisors
and documented research, as stated in the Company’s press release dated October 18th, 2023, which was filed with the
SEC on a Report on Form 6-K, the Company announced several corporate governance enhancements to further align the Company’s profile
with international standards and best practices. Therefore, since September 2023 and following the last Annual General Meeting, the Company’s
Board of Directors has been reduced from nine to seven directors, out of which six are independent directors.
Proposed Compensation for Non-Executive
Directors (other than the Non-Executive Chairman)
As part of these updates and to continue to attract
and retain world-class non-executive directors, on October 12th, 2023 and October 15th, 2023, the Compensation Committee
and the Board of Directors, respectively, approved and recommend that the Company’s shareholders approve, a cash annual fee
to all remaining Non-Executive Directors (as defined below) which shall be effective as of October 1, 2023, the beginning of the fourth
quarter of 2023. If this proposal is approved, the following non-executive members of the Board of Directors will be entitled to
the proposed cash annual fee: Mr. Oded Gera, Mr. Roni Kleinfeld, Mr. Chris Moran, Mr. Simon Anthony-Fried, and General (Ret.) Michael
Garrett and any other future non-executive director appointed in accordance with the Company’s Amended and Restated Articles of
Association following the Meeting (the “Non-Executive Directors”).
Currently, in accordance with the Company’s
Compensation Policy as approved by the Company’s shareholders in June 2022 (the “Policy”), the Non-Executive
Directors are not entitled to any cash fees, and are only compensated with restricted share units (“RSUs”) under the
annual equity-based plan for non-executive directors as follows:
One-time grant of 30,000 RSUs upon joining and
grants of 10,000 RSUs per annum thereafter; all grants will vest over three-years (some additional grants of RSUs are given to committee
members and committee chairs).
Background and Rationale for Proposed Update
The Company undertakes regular reviews of the
fees and equity-based compensation paid to Non-Executive Directors. The purpose of doing so is to ensure that the Company maintains the
ability to remunerate Non-Executive Directors at a level that is commensurate with market rates and as necessary to continue to attract
and retain directors of the appropriate level of experience and expertise.
The Compensation Committee and the Board of Directors
considered the fact that in the last four years, the Company’s Non-Executive Directors did not receive cash fees. Additionally,
in the past three years, there have been considerable additional demands placed on directors due to increased corporate activity, size
of the Company, and relevant regulatory requirements.
The Present Situation
Considering the present Company’s directors’
extended time commitment, the increased size of the Company and the market rate needed to attract qualified members, the Compensation
Committee and the Board of Directors have each decided it is warranted to adjust the compensation of Non-Executive Directors.
The Compensation Committee and the Board of Directors
also recognized that these additional demands have resulted in a significant expansion of time commitment for each of the Company’s
current directors. Based on these factors and the need to continue to both attract and retain qualified directors, the Compensation Committee
and the Board of Directors determined the proposed update to Non-Executive Director remuneration was warranted.
Studying Benchmarks and Formally published
Relevant Industry Research
To determine the appropriate remuneration structure
going forward, the Compensation Committee and the Board of Directors conducted an analysis of Non-Executive Director compensation, including
consulting with outside expert subject-matter advisors as needed and benchmarking against the “Spencer Stuart Board index for US
Technology Companies – 2022” (“Spencer Stuart”) report. Components of this analysis included:
| 1. | Total compensation for non-executive directors |
| 2. | % of the total that is granted in RSUs/options; and |
| 3. | % of the total that is paid in cash. |
To ensure overall alignment with comparable companies,
the Compensation Committee and the Board of Directors evaluated all three variables above that were chosen from over 60 companies with
annual revenues between $500 million to $1 billion, taking into consideration each company’s value, its industry and markets, its
growth rate, its manpower, its acquisitions rate, its size of business-legal activities and geographical spread.
Conclusions and Recommendations
The Compensation Committee and the Board of Directors
believes that providing an annual cash fee to Non-Executive Directors complements the current RSU grants and would serve to continue to
attract and retain qualified directors with the appropriate skills and experience to provide robust independent oversight. The Compensation
Committee and the Board of Directors believe it is fair and reasonable in all the relevant circumstances relating to the Company’s
affairs, the nature, extent and liabilities associated with service as a Non-Executive Director or otherwise by reference to prevailing
corporate governance standards and practices.
Therefore, the Compensation Committee and Board
of Directors consider it appropriate that all of the Non-Executive Directors, either currently serving or who will be appointed or
elected in the future, be compensated, through a compensation mechanism that will take into account the time, attention and expertise
required by such directors, and that will serve to attract directors with the appropriate skills and experience applicable to the Company’s
industry and needs.
Following the benchmark analysis by Spencer Stuart
as well as consultations with leading US law firms and US investment bankers described above, and for the above reasons, the Compensation
Committee and the Board of Directors recommend that the Company’s shareholders approve granting Non-Executive Directors
with a cash annual fee, in addition to any RSUs annual grants, in accordance with the following terms (the “Non-Executive Directors
Cash Annual Fee”):
Member of the Board of Directors - $80,000.
Member of the Board of Director and a Chairman
of a committee(s) of the Board of Directors- $90,000.
Member of the Board of Directors and a participant
of a committee(s) of the Board of Directors- $85,000.
The Non-Executive Directors Cash Annual Fee will
be paid on a quarterly basis, in U.S. dollars or in NIS, plus VAT, if applicable, and shall apply to the Non-Executive Directors effective
as of October 1st, 2023, or to such non-executive directors that will be appointed or elected in the future, effective from
their respective appointment or election.
Company Compensation Policy
The Non-Executive Directors Cash Annual Fee exceeds
the limitations of the Policy. Accordingly, the Compensation Committee and the Board of Directors studied the inputs from legal advisors
and the Spencer Stuart research, have considered all relevant considerations and discussed all matters required under the Companies Law
and the regulations promulgated thereunder, including, among others:
| (a) | the Non-Executive Directors’ skills, expertise, professional
experience, and achievements; |
| (b) | the Non-Executive Directors scope of responsibilities as
members of the Board of Directors; and |
| (c) | a comparison between the Non-Executive Directors Cash Annual
Fee and compensation granted to other non-executive directors in similar high-tech companies. |
Accordingly, the Compensation
Committee and Board of Directors determined that granting the Non-Executive Directors Cash Annual Fee, while exceeding the limitations
of the Policy, is necessary and in the Company’s best interest.
The shareholders of the
Company are requested to adopt the following resolution:
“RESOLVED, to
approve granting the Non-Executive Directors Cash Annual Fee as of October 1, 2023, as set forth in the Proxy Statement.”
The above resolution
requires the affirmative vote of a Special Majority.
Please note that the
Company considers it highly unlikely that any of our shareholders is a controlling shareholder or has a personal interest in this proposal.
However, as required under Israeli law, the enclosed form of proxy requires that you specifically indicate if you are a controlling shareholder
or have a personal interest in this proposal. If you indicate this effect – the Company will not be able to count your vote with
respect to this proposal.
The Board of Directors unanimously recommends
that the shareholders vote FOR the above proposal.
PROPOSAL 2
APPROVAL OF A COMPENSATION PACKAGE FOR THE COMPANY’S
NON-EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS, DR. YOAV NISSAN-COHEN
In accordance with feedback from the Company’s
shareholders, and a deliberative process by the Board as well as after consultation with US corporate governance advisors and documented
research, as stated in the Company’s press release dated October 18th, 2023, which was filed with the SEC on a Report
on Form 6-K.
Based on Shareholders’ feedback and after
careful consideration, as part of the above-mentioned enhancements of corporate governance to further align the Company’s profile
with international standards and best practices, the Board of Directors determined to separate the role of Chairman from the role of a
CEO. Mr. Stern continues to serve as the Company’s Chief Executive Officer.
On September 13th, 2023, Dr. Nissan-Cohen
was elected as a Non-Executive Chairman, due to his long-term proven track record including having served as CEO of large public companies.
Dr. Yoav Nissan-Cohen's career covers almost 40
years of scientific research, technology development, and executive management in the high-tech industry. He started his career as
a research scientist in the General Electric R&D Center in New York, worked at National Semiconductor, was one of the founders
of Tower Semiconductor where he served as a CEO, took the company public in Nasdaq and built a $1.5 billion advanced semiconductor facility.
Dr. Nissan-Cohen also started and managed several companies. Dr. Nissan-Cohen holds a Ph.D. degree in Physics from the Hebrew University
in Jerusalem.
On October 12th, 2023, and October
15th, 2023 (the “Grant Date”), the Compensation Committee and the Board of Directors, respectively, approved
a compensation package for Dr. Nissan-Cohen’s services as the Company’s Non-Executive Chairman of the Board of Directors.
The services of Dr. Nissan-Cohen will include such duties as customarily associated with such position and as may otherwise be assigned
and/or designated to such position by the Board of Directors and/or any applicable law from time to time.
Background and Rationale for Proposed Compensation
Package
In order to provide appropriate remuneration for
his services as Non-Executive Chairman, the Compensation Committee and the Board of Directors conducted a broad analysis which included
the reliance on outside advisors as well as benchmarking reports as appropriate. The analysis included the following components:
In analyzing the proper total compensation for
the Non-Executive Chairman, the Company has consulted with advisors from compensation department of US law firms, as well as used Spencer
Stuart industry research of high-tech public companies’ boards of directors. In the analysis of the study, the Company has chosen
the
| 1. | Total compensation for non-executive directors; |
| 2. | % of the total that is granted in RSUs/options; |
| 3. | % of the total that is paid in cash; and |
| 4. | The “premium” over the above which is paid to a “non-executive Chairman.” |
To ensure overall alignment with comparable companies,
the Compensation Committee and the Board of Directors evaluated the four variables above, across over 60 companies that were analyzed
by Spencer Stuart, to determine the proposed Non-Executive Chairman compensation. Based on this analysis, the Committee determined that,
on average, the additional compensation paid to a non-executive Chairman within the benchmarking group was approximately $60,000 over
and above the compensation paid for service as a Non-Executive Director.
Proposed Compensation Package
Based on its analysis, as detailed above, the
Compensation Committee and Board of Directors have approved the following compensation to be paid to Dr. Nissan-Cohen and requested shareholder
approval for the following (“Dr. Nissan-Cohen’s Compensation”):
| ● | RSUs under the Non-Executive Directors’ annual equity-based
plan- According to the Policy as previously approved by the shareholders, as a Non-Executive Chairman of the Board of Directors,
Dr. Nissan-Cohen will be entitled to a grant of 40,000 RSUs, under the non-executive directors’ annual equity-based plan and in
accordance with the terms as described in the Policy. |
| ● | Cash Fee. In consideration for Dr. Nissan-Cohen’s
special background as a supplier of services as non-executive Chairman, he will be entitled to a yearly payment in the aggregate amount
of $150,000 per annum (consisting of $90,000 as a director and a chairman of a committee, plus a $60,000 premium for serving as a non-executive
Chairman, plus VAT, if applicable), which will be paid by the Company on a quarterly basis, as of September 13th, 2023, the
date of his appointment as Chairman. |
| ● | One-Time grant of RSUs: In order to better align his
interests with those of shareholders, the Company proposes to grant Dr. Nissan-Cohen with 140,000 RSUs, to be vested over a 3-year period
as of the Grant Date, a third of it at the end of each year. |
| ● | Insurance, Indemnification and Exculpation. Dr. Nissan-Cohen
will continue to be entitled to the same insurance, indemnification and exculpation arrangements, as are currently in effect for all
of the Company’s officers and directors. |
The Compensation Committee and the Board of Directors
have submitted this proposal for shareholder approval given that Dr. Nissan-Cohen’s Compensation exceeds the limitations of the
Policy. Accordingly, the Compensation Committee and the Board of Directors have considered all relevant considerations and discussed all
matters required under the Companies Law and the regulations promulgated thereunder, including, among others:
(a) Mr. Nissan-Cohen’s compensation reflects
a fair and reasonable value for his services and is considered customary for such positions in companies of similar scopes of activities,
inter alia, based on the presented benchmark analysis of similar companies; and
(b) Dr. Nissan-Cohen’s experience in his
previous duties.
The Compensation Committee and the Board of Directors
believe that Dr. Nissan-Cohen’s Compensation is reasonable under the circumstances, including existing market conditions, and that
the approval thereof is in the best interests of the Company.
The shareholders of the Company are requested
to adopt the following resolution:
“RESOLVED,
to approve Dr. Nissan-Cohen’s Compensation as set forth in the Proxy Statement, effective as of September 13, 2023.”
The above resolution
requires the affirmative vote of a Special Majority.
Please note that the
Company considers it highly unlikely that any of our shareholders is a controlling shareholder or has a personal interest in this proposal.
However, as required under Israeli law, the enclosed form of proxy requires that you specifically indicate if you are a controlling shareholder
or have a personal interest in this proposal. If you indicate this effect – the Company will not be able to count your vote with
respect to this proposal.
The Board of Directors unanimously recommends
that the shareholders vote FOR the above proposal.
PROPOSAL 3
TO APPROVE A COMPENATION
PACKAGE FOR THE COMPANY’S CHIEF EXECUTIVE OFFICER, MR. YOAV STERN
Mr.
Yoav Stern served as the Company’s Chief Executive Officer until September 7, 2023, was compensated in accordance with the Amended
and Restated Management Services Agreement (as adjusted to currency exchange ratios), approved by the Company’s shareholders on
July 7, 2020, through his fully owned entity, DoubleShore Inc. (the “Previous Agreement” and “SP”,
respectively).
The
Previous Agreement was signed with the SP for services to be supplied by Mr. Stern as a non-director CEO of the Company. Fourteen months
later, Mr. Stern was asked to join the Board of Directors and become its chairman. Neither SP nor Mr. Stern received any additional compensation
or any other benefit after these additional 2 positions.
The
Board of Directors believes that Mr. Stern performance in his role as a CEO, and later as a CEO and Chairman exceeded all expectations.
In his first six months in office, as a CEO, Mr. Stern practically saved Nano Dimension from probable bankruptcy, during the Covid-19
pandemic of 2020. Mr. Stern later changed and developed the Company’s strategy and contributed to its growth in revenues from 2021
to 2023 by approximately 1100%, while improving gross margins, performing six acquisitions, leading an organic growth of approximately
30-45% during 2023, and raising all the capital needed to perform all of the above, and potentially much more. During the same period
the Company’s personnel grew from 75 to 550, performing research and development, manufacturing and go-to-market functions in the
UK, the Netherlands, Switzerland, Germany, U.S. and Israel. The Company’s portfolio has grown from one to over 15 new product lines.
Accordingly,
on October 12th, 2023, and on October 15th, 2023, the Compensation Committee and
the Board of Directors, respectively, approved and recommends that shareholders of the Company approve an amendment to the Previous
Agreement with SP, to be effective as of January 1st, 2024. The amendment to the Previous Agreement will include the following
items (the “Amendment”):
| ● | Services Fees. In consideration for Mr. Stern’s
services as Chief Executive Officer, as of January 1st, 2024 (the “Effective Date”), SP will be entitled
to the same monthly advisory fee, reimbursement of business expenses and certain severance benefits as in the Previous Agreement, as
set forth in sections 4, 5 and 11 of the Previous Agreement (the “Services Fees”). |
| ● | One-Time Grant of RSUs. The Company will grant on
the Effective Date and in each renewed term of the Amendment as detailed below, Mr. Stern with 1,400,000 RSUs, which will vest at the
end of each quarter for a total period of four years, as of the Grant Date (“RSUs to Mr. Stern”). |
| ● | Insurance, Indemnification and Exculpation. Mr. Stern
will continue to be entitled to the same insurance, indemnification and exculpation arrangements, as are currently in effect for all
of the Company’s other officers and directors. |
| ● | Term. The Amendment will be effective as of the Effective
Date, for a period of 12 months (the “Term”) and may be renewed by mutual consent of the Company’s Board of
Directors and SP, for up to 3 years. |
| ● | Termination
and Severance Payments. Each party may terminate the Amendment after 6 months, using
a 3-month advance notice period. |
(i) In case the Amendment will
not be replaced by a new contract following the Term in accordance with the prior notice above, Company will pay SP $950,000 as severance
payment, and all non-vested RSUs to Mr. Stern will be vested upon notice of termination.
(ii) In case the Amendment will
be terminated by the Company without Cause’ (as defined in the Previous Agreement), and before the lapse of six months from each
renewal of the Amendment (if renewed for additional years), the Company will pay SP the rest of the monthly Services Fees for that specific
year, and an additional $950,000 as severance payment. In addition, all non-vested RSUs to Mr. Stern will be fully vested upon termination
notice.
The Amendment terms are in accordance with
the Policy as previously approved by its shareholders in 2022. Accordingly, the Compensation Committee and the Board of Directors
recommend to the shareholders to approve the Amendment, for the following reasons:
(a) the Amendment includes the same Services Fees
fixed components as the Previous Agreement as a CEO, reflecting the contribution of Mr. Stern to the Company within the scope of the CEO
services given to the Company;
(b) the value of the compensation was determined
while taking into consideration Mr. Stern’s deep understanding of the Company’s business and record in ensuring continuity
in the Company’s business and his valuable contribution to the Company’s success in the last four years.
(c) the value of the compensation was determined
while taking into consideration the position, scope of responsibility and previous compensation arrangements of Mr. Stern, and his contributions
to the Company’s growth;
(d) since September 7th, 2023, Mr.
Stern has not been paid for his services as full time CEO, and it is therefore reasonable to approve the requested compensation as of
the beginning of 2024; and
(e) the Amendment terms are considered customary
for such positions in US companies of similar scopes of activities, inter alia.
Accordingly, the Compensation
Committee and Board of Directors determined that approving the Amendment which will be effective as of the Effective Date, in accordance
with the Policy is necessary and in the Company’s best interest.
The shareholders of the
Company are requested to adopt the following resolution:
“RESOLVED,
to approve a compensation package for the Company’s Chief Executive Officer, Mr. Yoav Stern in accordance with the Amendment terms,
as set forth in the Proxy Statement.”
The above resolution requires the affirmative vote of a Special Majority.
Please note that the Company considers it highly
unlikely that any of our shareholders is a controlling shareholder or has a personal interest in this proposal. However, as required under
Israeli law, the enclosed form of proxy requires that you specifically indicate if you are a controlling shareholder or have a personal
interest in this proposal. If you indicate this effect – the Company will not be able to count your vote with respect to this proposal.
The Board of Directors unanimously recommends
that the shareholders vote FOR the above proposal.
Your vote is important!
Shareholders are urged to complete and return their proxies promptly in order to, among other things, ensure action by a quorum and
to avoid the expense of additional solicitation. If the accompanying proxy is properly executed and returned in time for voting, and a
choice is specified, the shares represented thereby will be voted as indicated thereon. EXCEPT AS MENTIONED OTHERWISE IN THIS PROXY STATEMENT,
IF NO SPECIFICATION IS MADE, THE PROXY WILL BE VOTED IN FAVOR OF THE PROPOSALS DESCRIBED IN THIS PROXY STATEMENT.
Proxies and all other
applicable materials should be sent to the Company’s office at Ilan Ramon 2, Ness Ziona.
ADDITIONAL INFORMATION
The Company is subject
to the informational requirements of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”),
as applicable to foreign private issuers. Accordingly, the Company files reports and other information with SEC. All documents which the
Company will file on the SEC’s EDGAR system will be available for retrieval on the SEC’s website at http://www.sec.gov.
As a foreign private
issuer, the Company is exempt from the rules under the Exchange Act prescribing certain disclosure and procedural requirements for proxy
solicitations. In addition, the Company is not required under the Exchange Act to file periodic reports and financial statements with
the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. The Notice of
the Special General Meeting of Shareholders and the Proxy Statement have been prepared in accordance with applicable disclosure requirements
in the State of Israel.
YOU SHOULD RELY ONLY
ON THE INFORMATION CONTAINED IN THIS PROXY STATEMENT OR THE INFORMATION FURNISHED TO YOU IN CONNECTION WITH THIS PROXY STATEMENT WHEN
VOTING ON THE MATTERS SUBMITTED TO SHAREHOLDER APPROVAL HEREUNDER. THE COMPANY HAS NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION
THAT IS DIFFERENT FROM WHAT IS CONTAINED IN THIS DOCUMENT. THIS PROXY STATEMENT IS DATED OCTOBER 18, 2023. YOU SHOULD NOT ASSUME THAT
THE INFORMATION CONTAINED IN THIS DOCUMENT IS ACCURATE AS OF ANY DATE OTHER THAN OCTOBER 18, 2023, AND THE MAILING OF THIS DOCUMENT TO
SHAREHOLDERS SHOULD NOT CREATE ANY IMPLICATION TO THE CONTRARY.
By Order of the Board
of Directors
NANO DIMENSION LTD.
Dr. Yoav Nissan-Cohen,
Chairman of the Board of Directors
10
Exhibit 99.4
NANO DIMENSION LTD.
PROXY
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD
OF DIRECTORS.
The undersigned hereby appoints,
Dr. Yoav Nissan-Cohen, Chairman of the Board of Directors and Mr. Tomer Pinchas, Chief Operating Officer and acting Chief Financial Officer,
and each of them, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote
on behalf of the undersigned all the Ordinary Shares of Nano Dimension Ltd. (the “Company”) which the undersigned is
entitled to vote at the Extraordinary General Meeting of Shareholders (the “Meeting”) to be held at the offices of
the Company at 2 Ilan Ramon, Ness Ziona 7403635, Israel, on December 13, 2023, at 16:00 p.m., Israel time, and at any adjournments or
postponements thereof, upon the following matter, which is more fully described in the Notice of Extraordinary General Meeting of Shareholders
and Proxy Statement relating to the Meeting.
This Proxy, when properly
executed, will be voted in the manner directed herein by the undersigned. If no direction is made with respect to any matter, this Proxy
will be voted FOR such matter. Any and all proxies heretofore given by the undersigned are hereby revoked.
(Continued and to be signed on the reverse side)
NANO DIMENSTION LTD.
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Date of Meeting: December 13, 2023
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED
ENVELOPE. PLEASE
MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE ☒
1. |
To approve a Cash Annual Fee to all Non-Executive
Directors as of October 1, 2023, as set forth in the Proxy Statement. |
|
☐ |
FOR |
☐ |
AGAINST |
☐ |
ABSTAIN |
1a. |
Do you confirm that you are a controlling shareholder of the Company and/or have a personal interest (as such terms are defined in the Companies Law and in the Proxy Statement) in Proposal No. 1?* |
|
|
|
* if you indicate YES for this item 2a, YOUR SHARES WILL NOT BE COUNTED for vote on Proposal
No. 1. |
|
|
|
☐ YES I am/We are controlling shareholder of the Company and/or have a personal interest
in Proposal No. 1 |
|
|
2. |
To approve a compensation package to the Company’s Chairman of
the Board of Directors, Dr. Nissan-Cohen, as of September 13, 2023, as set forth in the Proxy Statement. |
|
☐ |
FOR |
☐ |
AGAINST |
☐ |
ABSTAIN |
2a. |
Do you confirm that you are a controlling shareholder of the Company and/or have a personal interest (as such terms are defined in the Companies Law and in the Proxy Statement) in Proposal No. 2?* |
|
|
|
* if you indicate YES for this item 2a, YOUR SHARES WILL NOT BE COUNTED for vote on Proposal
No. 2. |
|
|
|
☐ YES I am/We are controlling shareholder of the Company and/or have a personal interest
in Proposal No. 2. |
3. |
To approve a compensation package to the Company’s Chief Executive Officer, Mr. Yoav Stern, as of January 1, 2024, in accordance with the Amendment terms, as set forth in the proxy statement.” |
|
☐ |
FOR |
☐ |
AGAINST |
☐ |
ABSTAIN |
3a. |
Do you confirm that you are a controlling shareholder of the Company and/or have a personal interest (as such terms are defined in the Companies Law and in the Proxy Statement) in Proposal No. 3?* |
|
|
|
* if you indicate YES for this item 3a, YOUR SHARES WILL NOT BE COUNTED for vote on Proposal
No. 3. |
|
|
|
☐ YES I am/We are controlling shareholder of the Company and/or have a personal interest
in Proposal No. 3. |
A “controlling shareholder”
is any shareholder that can direct the Company’s activities (other than by means of being a director or office holder of the Company).
A person is presumed to be a controlling shareholder if he or she holds or controls, by himself or together with others, one half or more
of any one of the “means of control” of a company; in the context of a transaction with an interested party, a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company,
is also presumed to be a controlling shareholder. “Means of control” is defined as any one of the following: (i) the right
to vote at a general meeting of a company, or (ii) the right to appoint directors of a company or its chief executive officer.
“Personal interest”
is defined under the Israeli Companies Law as: (1) a shareholder’s personal interest in the approval of an act or a transaction
of the Company, including (i) the personal interest of any of his or her relatives (which includes for these purposes foregoing shareholder’s
spouse, siblings, parents, grandparents, descendants, and spouse’s descendants, siblings, and parents, and the spouse of any of
the foregoing); (ii) a personal interest of a corporation in which a shareholder or any of his/her aforementioned relatives serve as a
director or the chief executive officer, owns at least 5% of its issued share capital or its voting rights or has the right to appoint
a director or chief executive officer; and (iii) a personal interest of an individual voting via a power of attorney given by a third
party (even if the empowering shareholder has no personal interest), and the vote of an attorney-in-fact shall be considered a personal
interest vote if the empowering shareholder has a personal interest, and all with no regard as to whether the attorney-in-fact has voting
discretion or not, but (2) excludes a personal interest arising solely from the fact of holding shares in the Company.
In their discretion, the proxies are authorized
to vote upon such other matters as may properly come before the Meeting or any adjournment or postponement thereof.
|
|
|
|
|
NAME |
|
SIGNATURE |
|
DATE __, 2023 |
|
|
|
|
|
|
|
|
|
|
NAME |
|
SIGNATURE |
|
DATE __, 2023 |
Please sign exactly as your name appears on this
Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, trustee or guardian, please give
full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such.
If signer is a partnership, please sign in partnership name by authorized person.
Nano Dimension (NASDAQ:NNDM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Nano Dimension (NASDAQ:NNDM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024